Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.74 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207806 | 0.91 | KDR (0.74) | KDRCHEK1DAOCYP19A1CDK5 | |
| SCHEMBL29370693 | 0.86 | KDR (1.00) | KDRCHEK1DAOCDK5CDK5R1 | |
| SCHEMBL5076094 | 0.86 | KDR (1.00) | KDRCHEK1DAOCDK5CDK5R1 | |
| SCHEMBL7084245 | 0.78 | FGFR1 (0.74) | KDRDAOKDM4EHPGDHSD17B10 | |
| SCHEMBL5078033 | 0.78 | KDR (0.65) | KDRCHEK1KDM4EHPGDPDGFRB | |
| SCHEMBL3963947 | 0.77 | CDK5 (0.68) | KDRCHEK1DAOCDK5CDK5R1 | |
| SCHEMBL5207592 | 0.77 | KDR (0.69) | KDRCHEK1DAOCYP19A1CDK5 | |
| SCHEMBL17100080 | 0.77 | KDR (0.64) | KDRCHEK1DAOCDK5CDK5R1 | |
| SCHEMBL27489248 | 0.77 | KDR (0.79) | KDRCHEK1DAOKDM4EHPGD | |
| SCHEMBL30305373 | 0.76 | KDR (0.78) | KDRCHEK1DAOCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259235-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | claimed |
| US-6420382-B2 | QUINOLIN-2-ONE DERIVATIVES TO TREAT ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND INFLAMMATORY DISEASES | MERCK & CO., INC. | 2002-07-16 | — | — | US | claimed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | claimed |
| US-20010044451-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | claimed |
| WO-2008022467-A1 | 2-SUBSTITUTED AZAIN DOLES AND 2 SUBSTITUTED THIENOPYRROLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008022467-A1 | 2-SUBSTITUTED AZAIN DOLES AND 2 SUBSTITUTED THIENOPYRROLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2008-02-28 | — | — | WO | disclosed |
| EP-1259235-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1259235-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1259236-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1259236-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6420382-B2 | QUINOLIN-2-ONE DERIVATIVES TO TREAT ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND INFLAMMATORY DISEASES | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-20010047007-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2001-11-29 | — | — | US | disclosed |
| US-20010044451-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | disclosed |
| US-6313138-B1 | FOR THERAPY OF ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES IN MAMMALS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001062252-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044451-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885DAO 1113/4885 |
| US-20010047007-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885DAO 1113/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | KDR 318/4885CHEK1 3711/4885DAO 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.